欧盟中国商会声明
对欧盟拟根据《国际采购工具》对中资企业采取限制性措施表示严重关切
2025年6月2日，比利时布鲁塞尔
欧盟中国商会注意到，媒体当日报道，欧盟成员国依据《国际采购工具》（IPI）批准对中方采取惩罚性措施的决定，据该决定，中国企业未来5年将被限制参与价值超过500万欧元的欧盟医疗器械公共招标项目。欧盟中国商会对欧方这一决定深表失望，对欧方将限制中企参与欧洲当地医疗采购市场表示严重关切。
IPI是欧方的单边工具，欧方这一有针对性的做法释放出令人担忧的信号，不仅加剧了中欧经贸关系的复杂性，也与欧盟所倡导的开放市场和公平竞争原则相悖。
值得指出的是，一味追求所谓“市场平等”并不能脱离历史与现实的逻辑。长期以来，欧洲医疗器械企业在中国市场享受到了高度的开放红利，深度参与中国医疗体系的现代化进程，取得了显著发展。欧方6月2日的决定未能充分考虑这一背景，将对中欧多年来在医疗领域积累的互信与合作基础造成冲击。
当前，全球贸易体系正面临高度不确定性。部分国家不断推出单边关税措施，严重扰乱全球市场秩序。在此背景下，中欧作为全球主要经济体，理应携手维护自由贸易与多边合作，而非单边设限、加剧紧张。
中国企业一贯秉持合法合规、诚信经营的原则，在欧盟市场积极拓展业务，为当地经济发展、技术创新和就业吸纳做出了实质贡献。
我们敦促欧方重新审视IPI对中企在欧发展拟采取惩罚性措施的必要性与长远影响，避免将政策工具演变为贸易壁垒。坚持开放、公正、非歧视的市场环境，不仅符合中欧共同利益，也有助于提振全球经济信心与可持续发展前景。
欧盟中国商会将继续秉持建设性态度，与欧方各界保持沟通，坚定维护会员企业的合法权益。我们坚信，中欧双方通过对话与合作，有能力妥善管控分歧，推动全球经济迈向更加开放、稳定和包容的未来。
CCCEU Statement on EU Member States' Approval of Restrictive Measures Against Chinese Enterprises Under the International Procurement Instrument (IPI)2 June 2025, Brussels, BelgiumThe China Chamber of Commerce to the EU (CCCEU) takes note that EU member states have reportedly approved restrictive measures under the International Procurement Instrument (IPI), limiting Chinese companies’ access to public procurement tenders in the medical device sector for contracts exceeding €5 million over a five-year period.The CCCEU expresses profound disappointment over this decision and serious concerns about the EU’s move to limit Chinese enterprises’ participation in the EU procurement market, particularly in the healthcare sector.The IPI is a unilateral instrument introduced by the EU. Its targeted application against Chinese enterprises sends a troubling signal—not only adding new complexity to China-EU economic and trade relations, but also contradicting the EU’s stated principles of openness, fairness, and non-discrimination in market access.It is important to underscore that any pursuit of “market reciprocity” must be based on an accurate understanding of historical and practical realities. For years, European medical device companies have enjoyed significant access to the Chinese market, playing a key role in supporting the modernization of China’s healthcare system and achieving substantial growth. The EU’s current decision fails to acknowledge this context and undermines the spirit of balanced engagement and mutual benefit.At a time when the global trade faces considerable uncertainty, and certain countries are resorting to unilateral tariff measures that disrupt global market order, China and the EU—as two major global economies—should jointly uphold free trade and multilateral cooperation, instead of introducing unilateral restrictions that escalate tensions.Chinese enterprises have consistently operated in compliance with laws and regulations, following principles of integrity and good faith. Their contributions to the EU—through investment, technological advancement, and job creation—are widely recognized and valued.The CCCEU urges the EU to reconsider the necessity and long-term implications of these restrictive measures under the IPI. Turning policy instruments into de facto trade barriers would not only harm bilateral interests but also weaken global confidence in economic recovery and sustainable development.We remain committed to constructive engagement. The CCCEU will continue to maintain open communication with all relevant EU stakeholders and defend the legitimate rights and interests of our member companies. We firmly believe that through dialogue and cooperation, China and the EU can effectively manage differences and work together toward a more open, stable, and inclusive global economy.
